The aim of the TMEN Human Sample Acquisition Core (HSAC) is the collection of human biological material with associated clinical information to facilitate translational research of the individual projects. This core will build on the already existing resources of the University of Michigan Prostate SPORE to make the best use of available resources. Quality assurance is maintained through the staff of the Prostate SPORE pathologists. Clinical consent and patient participation is conducted by Dr. Pienta through the Prostate Cancer Clinic at the University of Michigan. The informatics infrastructure of the Human Sample Acquisition Core is provided by an instance of caTissue as hosted by the Prostate SPORE and is coordinated by the Directors of the Division of Pathology Informatics. Specifically, the aim of the HSAC is to (i) collect blood for circulating tumor cells, white blood cells, and serum, (Ii) to collect bone marrow from aspirates and biopsies for mesenchymal cells, disseminated tumor cells and serum, and (iii) collect metastatic tissue from the University of Michigan Rapid Autopsy Program (RAP). Support for tissue banking and collection of tissue from the RAP is provided by the SPORE. Support is only being requested to collect and process blood and bone marrow.

Public Health Relevance

This TMEN will be focused on the mechanisms that regulate dormancy of skeletal metastases in prostate cancer. This core will oversee the operations of the entire Program to ensure that it moves forward in a direction that addresses this important clinical problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163124-03
Application #
8567743
Study Section
Special Emphasis Panel (ZCA1-SRLB-3)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$109,612
Indirect Cost
$69,098
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Valkenburg, Kenneth C; de Groot, Amber E; Pienta, Kenneth J (2018) Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 15:366-381
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Decker, A M; Taichman, L S; D'Silva, N J et al. (2018) Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 5:7-12
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619

Showing the most recent 10 out of 79 publications